Trial report in Hypertension (Dallas, Tex. : 1979), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
20 authors.
Anna C M KluiversDepartment of Internal Medicine, Division of Pharmacology and Vascular Medicine, Erasmus MC, University Medical Center, Rotterdam, the Netherlands (A.C.M. Kluivers, R.I.N., W.V., A.H.J.D.).ORCID 0000-0002-4115-372X
Rugina I NeumanDepartment of Internal Medicine, Division of Pharmacology and Vascular Medicine, Erasmus MC, University Medical Center, Rotterdam, the Netherlands (A.C.M. Kluivers, R.I.N., W.V., A.H.J.D.).
Langeza SalehDepartment of Obstetrics and Gynecology, Division Obstetrics and Fetal Medicine, Erasmus MC, University Medical Center, Rotterdam, the Netherlands (A.C.M. Kluivers, L.S., I.A.B., J.M.J.C., E.A.P.S.).ORCID 0000-0001-6219-3109
Henk RusscherDepartment of Clinical Chemistry, Erasmus MC, University Medical Center, Rotterdam, the Netherlands (H.R.).
Ingrid A BrusséDepartment of Obstetrics and Gynecology, Division Obstetrics and Fetal Medicine, Erasmus MC, University Medical Center, Rotterdam, the Netherlands (A.C.M. Kluivers, L.S., I.A.B., J.M.J.C., E.A.P.S.).
Jerome M J CornetteDepartment of Obstetrics and Gynecology, Division Obstetrics and Fetal Medicine, Erasmus MC, University Medical Center, Rotterdam, the Netherlands (A.C.M. Kluivers, L.S., I.A.B., J.M.J.C., E.A.P.S.).ORCID 0000-0001-8482-5138
Eric A P SteegersDepartment of Obstetrics and Gynecology, Division Obstetrics and Fetal Medicine, Erasmus MC, University Medical Center, Rotterdam, the Netherlands (A.C.M. Kluivers, L.S., I.A.B., J.M.J.C., E.A.P.S.).ORCID 0000-0001-6658-9274
Marijke C van der WeideDepartment of Obstetrics and Gynecology, Amsterdam University Medical Center, University of Amsterdam, the Netherlands (M.C.W., W.G., S.M.W.).ORCID 0000-0001-6979-1347
Joris van DrongelenDepartment of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, the Netherlands (J.D., R.R.S.).ORCID 0000-0002-4592-4288
Ralph R ScholtenDepartment of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, the Netherlands (J.D., R.R.S.).ORCID 0000-0002-7681-5703
Antonius E van HerwaardenDepartment of Clinical Chemistry, Radboud University Medical Center, Nijmegen, the Netherlands (A.E.H.).ORCID 0000-0002-5417-8272
Sanne J GordijnDepartment of Obstetrics and Gynecology, University of Groningen,University Medical Center Groningen, Groningen, the Netherlands (S.J.G.).ORCID 0000-0003-3915-8609
Anneke C Muller KoboldDepartment of Laboratory medicine, University of Groningen, University Medical Center Groningen, the Netherlands (A.C. Muller Kobold).ORCID 0000-0003-3457-4179
Wessel GanzevoortDepartment of Obstetrics and Gynecology, Amsterdam University Medical Center, University of Amsterdam, the Netherlands (M.C.W., W.G., S.M.W.).ORCID 0000-0002-7243-2115
Sharon M WesseliusDepartment of Obstetrics and Gynecology, Amsterdam University Medical Center, University of Amsterdam, the Netherlands (M.C.W., W.G., S.M.W.).ORCID 0000-0002-5927-6189
Maurits C F J de RotteLaboratory of Specialized Diagnostics and Research, Department of Laboratory medicine, Amsterdam University Medical Center, University of Amsterdam, the Netherlands (M.C.F.J.R.).
Robert AardenburgDepartment of Obstetrics and Gynecology, Zuyderland Medical Center, Heerlen, The Netherlands (R.A.).
Maarten RaijmakersDepartment of Clinical Chemistry, Zuyderland Medical Center, Heerlen, the Netherlands (M.R.).
Willy VisserDepartment of Internal Medicine, Division of Pharmacology and Vascular Medicine, Erasmus MC, University Medical Center, Rotterdam, the Netherlands (A.C.M. Kluivers, R.I.N., W.V., A.H.J.D.).ORCID 0000-0003-3796-9088
A H Jan DanserDepartment of Internal Medicine, Division of Pharmacology and Vascular Medicine, Erasmus MC, University Medical Center, Rotterdam, the Netherlands (A.C.M. Kluivers, R.I.N., W.V., A.H.J.D.).ORCID 0000-0002-5052-3585
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
backgroundA model based on the soluble Fms-like tyrosine kinase-1/placental growth factor ratio, gestational age, and the urinary protein-to-creatinine ratio (PRERISK calculator) has been developed to predict preeclampsia-related maternal-fetal complications. Here, we tested whether this model can reduce hospital admissions without increasing complication rates among women with suspected or confirmed preeclampsia.
methodsIn this multicenter, open-label, randomized controlled trial conducted at 5 Dutch medical centers, women with suspected or confirmed preeclampsia were randomly assigned to the intervention group, where admission was guided by the PRERISK score using a 5% cutoff, or to the control group receiving routine care with a concealed PRERISK score. Two co-primary outcomes were the incidence of maternal-fetal preeclampsia-related complications (noninferiority) and the proportion of women with a hospitalization ratio (=admission days/inclusion days) ≤0.05 (superiority).
resultsThe intervention and control groups included 442 and 435 women, respectively. In the intention-to-treat analysis, complications occurred in 41.6% of the intervention group versus 39.5% of the control group (adjusted relative risk 1.06 [95% CI, 0.92-1.22];
conclusionsRoutine screening with the PRERISK score and a 5% cutoff in patients with suspected or confirmed preeclampsia does not decrease hospitalization and is therefore not recommended. REGISTRATION: URL: https://onderzoekmetmensen.nl/nl/trial/48687; Unique identifier: NL63386.078.17, NL-OMON48687.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
PRERISK Study: A Randomized Controlled Trial Evaluating a sFlt-1/PlGF-Based Calculator for Preeclampsia Hospitalization. · full record | OpenQuestion